Royal Bank Of Canada reissued their buy rating on shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a report released on Friday, November 3rd. The firm currently has a $15.00 price target on the stock.
A number of other equities analysts have also recently issued reports on KPTI. Robert W. Baird reiterated a buy rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Jefferies Group LLC restated a buy rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Cantor Fitzgerald set a $18.00 price objective on shares of Karyopharm Therapeutics and gave the stock a buy rating in a research note on Thursday, October 12th. ValuEngine downgraded shares of Karyopharm Therapeutics from a hold rating to a sell rating in a research note on Thursday, August 31st. Finally, BidaskClub upgraded shares of Karyopharm Therapeutics from a sell rating to a hold rating in a research note on Friday, August 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $15.50.
Karyopharm Therapeutics (KPTI) opened at $10.71 on Friday. Karyopharm Therapeutics has a 1-year low of $7.48 and a 1-year high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts predict that Karyopharm Therapeutics will post -2.58 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was published by TrueBlueTribune and is the property of of TrueBlueTribune. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.truebluetribune.com/2017/11/14/karyopharm-therapeutics-inc-kpti-rating-reiterated-by-royal-bank-of-canada.html.
In other Karyopharm Therapeutics news, SVP Christopher Brett Primiano sold 4,958 shares of Karyopharm Therapeutics stock in a transaction on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mansoor Raza Mirza sold 2,882 shares of Karyopharm Therapeutics stock in a transaction on Friday, September 15th. The shares were sold at an average price of $11.00, for a total transaction of $31,702.00. Following the completion of the sale, the director now directly owns 2,882 shares of the company’s stock, valued at $31,702. The disclosure for this sale can be found here. In the last 90 days, insiders sold 15,653 shares of company stock worth $174,728. 14.71% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of KPTI. Wells Fargo & Company MN grew its position in Karyopharm Therapeutics by 114.6% in the 1st quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock worth $560,000 after purchasing an additional 23,284 shares in the last quarter. Bank of New York Mellon Corp grew its position in Karyopharm Therapeutics by 61.7% in the 1st quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock worth $2,332,000 after purchasing an additional 69,315 shares in the last quarter. Swiss National Bank grew its position in Karyopharm Therapeutics by 10.9% in the 1st quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after purchasing an additional 4,000 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Karyopharm Therapeutics in the 1st quarter worth about $1,128,000. Finally, Parametric Portfolio Associates LLC grew its position in Karyopharm Therapeutics by 38.6% in the 1st quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock worth $359,000 after purchasing an additional 7,789 shares in the last quarter. 59.23% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.